Swiss Rockets Appoints former Roche Senior Executive Tiffany Payette as Chief Corporate Affairs and Investor Relations Officer

Ms. Payette will lead Swiss Rockets’ corporate affairs, communications, and investor relations activities, supporting the company’s mission to build, grow, and partner biotech companies that translate scientific innovation into meaningful impact.

Ms. Payette joins Swiss Rockets from Roche, where she most recently served as Global Head of Roche Pharmaceuticals Communications. Her career spans more than 20 years across healthcare delivery, pharmaceuticals, and public affairs leadership. In these roles, she partnered closely with scientists, executives, and external stakeholders, led global teams, and supported complex partnerships and transactions, working closely with executive leadership and Investor Relations teams on corporate positioning, stakeholder engagement, and communications related to corporate strategy and performance.

“Tiffany brings a rare combination of deep scientific communications expertise, partnering experience, and executive leadership,” said Dr. Vladimir Cmiljanovic, Chief Executive Officer of Swiss Rockets AG. “Her background across early research, strategic collaborations, and global corporate affairs makes her an excellent fit for Swiss Rockets as we continue to build and scale our platform and portfolio companies.”

“I am excited to join Swiss Rockets at a time of strong momentum and ambition,” said Tiffany Payette. “Swiss Rockets’ unique model, combining company building, incubation and strategic partnerships, creates a powerful platform to advance science and engage partners and investors committed to long-term value creation.”

About Swiss Rockets AG

Swiss Rockets AG is an incubator and accelerator supporting the growth of biotech and precision healthcare companies with a focus on oncology. Its portfolio includes radioligand therapies, small molecules, and live-attenuated virus vaccines across preclinical and clinical stages.